AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14507293
Drug: Group W1
RxNorm normalized name: Neisseria meningitidis serogroup W135 conjugated Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group W1 (65% VO2max, 300 kcal in one daily walking bout)
Trial: 14507293
Drug: Group W2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group W2 (65% VO2max, 300 kcal in two daily walking bouts)
Trial: 11115683
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant use
Trial: 31618698
Drug: Decongestive therapies
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestive therapies
Trial: 26501831
Drug: Systemic magnesium
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic magnesium infusion (initial loading dose 30 mg/kg over 15 minutes followed by continuous infusion 10 mg/kg/h)
Trial: 26501831
Drug: Systemic magnesium
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic magnesium infusion
Trial: 24171961
Drug: Improved PAD
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved PAD (subcutaneous injection of bortezomib)
Trial: 24171961
Drug: PAD (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAD (conventional treatment)
Trial: 20508979
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (IT)
Trial: 18309943
Drug: Trimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodality therapy (cisplatin 100 mg/m² and fluorouracil 1,000 mg/m²/d for 4 days on weeks 1 and 5 concurrent with radiation therapy 50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection
Trial: 12702891
Drug: Mirtazapine 30‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30‐45 mg/day
Trial: 12702891
Drug: Paroxetine 20‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20‐30 mg/day
Trial: 12848626
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (15-25 mg)
Trial: 12848626
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate with 5 mg folic acid (15-25 mg)
Trial: 12848626
Drug: Subcutaneous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous methotrexate (15-25 mg)
Trial: 10589962
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (MMF, CsA, and prednisone)
Trial: 10589962
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of CsA (group B)
Trial: 10589962
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of triple therapy (group A)
Trial: 10589962
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of prednisone (group C)
Trial: 1872925
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil dietary supplementation (10 g/day)
Trial: 6343861
Drug: Acyclovir (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (1500 mg/m²/day for one week)
Trial: 3709648
Drug: MDL 72.222,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72.222, 20 mg (slow i.v. injection)
Trial: 18373843
Drug: GEM+X (gemcitabine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM+X (gemcitabine-based combination chemotherapy)
Trial: 16931265
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anterior capsule polishing)
Trial: 9091027
Drug: Doxazosin (1-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1-16 mg, mean final dose 6.1 mg)
Trial: 9091027
Drug: Nitrendipine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10-20 mg, mean final dose 15.6 mg)
Trial: 8365297
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion (2 g IV over 20 min followed by 2 g/h over 4 h)
Trial: 8365297
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate bolus (2 g over 20 min followed by placebo infusion)
Trial: 8365297
Drug: Placebo (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (loading dose and infusion)
Trial: 27301489
Drug: Organisational change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organisational change intervention including smoke-free policy development, staff training, educational resources, and free nicotine replacement therapy.
Trial: 25187104
Drug: Glucose with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose with 2.4 g · kg(‐1) · day(‐1) amino acids
Trial: 18246696
Drug: Erythromycin 200
RxNorm normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 200 mg 4 times daily for adults; 20 to 40 mg/kg daily in 4 divided doses for children
Trial: 18246696
Drug: Placebo (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (an emollient cream)
Trial: 16540709
Drug: Intermittent hypoxia
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent hypoxia training (IHT) in hypoxia (FiO2 = 14.5%); 6 weeks duration; included two weekly high-intensity training sessions.
Trial: 16540709
Drug: Normoxia training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoxia training (Nor group; FiO2 = 20.9%); 6 weeks duration; included two weekly high-intensity training sessions.
Trial: 9412256
Drug: 0.4 g.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g.kg-1 HBOC-201
Trial: 9412256
Drug: 3 ml.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml.kg-1 6% HES 70,000/0.5
Trial: 8241226
Drug: Cyclosporine target
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine target trough level reduced from 400-600 micrograms/L to 200-400 micrograms/L (Group A)
Trial: 8241226
Drug: Cyclosporine target
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine target trough level maintained at 400-600 micrograms/L (Group B)
Trial: 22537207
Drug: Once-daily (q.d.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (q.d.) pramipexole
Trial: 22537207
Drug: Three-times-daily (t.i.d.)
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times-daily (t.i.d.) pramipexole
Trial: 19190632
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg m(‐2), d1, d8, 100‐min infusion) and Oxaliplatin (100 mg m(‐2), d1)
Trial: 19190632
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and Oxaliplatin combination
Trial: 12548062
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg)
Trial: 12194635
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg)
Trial: 12374899
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg)
Trial: 9366100
Drug: Piretanide 6
RxNorm normalized name: piretanide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide 6 mg (PIR)
Trial: 9366100
Drug: Altizide 15
RxNorm normalized name: althiazide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altizide 15 mg - Spironolactone 25 mg (ALT-SP)
Trial: 9366100
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (PIR, HCT, ALT-SP)
Trial: 3910541
Drug: Rosoxacin 150
RxNorm normalized name: rosoxacin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosoxacin 150 mg twice daily for 10 days
Trial: 3910541
Drug: Triple tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple tetracycline (Deteclo) 300 mg twice daily for 10 days
Trial: 31880078
Drug: Home-based pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based pulmonary rehabilitation (8 weeks, one home visit and seven once-weekly telephone calls)
Trial: 31880078
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (weekly social telephone calls)
Trial: 22801416
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin/10 mg ezetimibe
Trial: 15899726
Drug: Metabolife Ephedra
RxNorm normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolife Ephedra Free (half the normal recommended dose)
Trial: 12789955
Drug: Oral‐B Stages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Stages toothbrushes
Trial: 9583761
Drug: Levodopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (100 mg) plus benserazide (25 mg) taken three times per day for 28 days
Trial: 9450173
Drug: Tablet (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (treatment A)
Trial: 9450173
Drug: Capsule (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule (treatment B, Gramidil)
Trial: 21771770
Drug: IVIG 0.5‐1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 0.5‐1.0 g/kg
Trial: 21771770
Drug: IVIG 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 0.5 g/kg
Trial: 21771770
Drug: IVIG 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1.0 g/kg
Trial: 19416445
Drug: Baseline (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (before any dental treatment)
Trial: 8498314
Drug: Amlodipine 1.25
RxNorm normalized name: levamlodipine 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 1.25 mg daily
Trial: 8498314
Drug: Amlodipine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 5.0 mg daily
Trial: 8498314
Drug: Amlodipine 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10.0 mg daily
Trial: 8498314
Drug: Amlodipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (all doses > 1.25 mg)
Trial: 3549810
Drug: 3% topical
RxNorm normalized name: Triaz 3% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% topical minoxidil applied twice daily for 64 weeks
Trial: 3549810
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks, then 3% topical minoxidil for 52 weeks
Trial: 3549810
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of 3% topical minoxidil for a second year
Trial: 26559015
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg.kg(‐1))
Trial: 24566571
Drug: Capilen® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capilen® cream
Trial: 20408017
Drug: Liquid carbon
RxNorm normalized name: calcium carbonate Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid carbon dioxide cooling shirt (CC)
Trial: 18758393
Drug: Antiretroviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drugs (lamivudine, stavudine, zidovudine, nevirapine, nelfinavir, ritonavir, lopinavir) measured in breast milk using a novel extraction method and high-performance liquid chromatography-tandem mass spectrometry.
Trial: 10500060
Drug: Norfloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (800 mg/day)
Trial: 10500060
Drug: Amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanic acid (1500 mg/day)
Trial: 1986897
Drug: Nitroprusside administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside administered using Abbott infusion pump
Trial: 1986897
Drug: Nitroprusside administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside administered using IMED infusion pump
Trial: 1986897
Drug: Nitroprusside administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside administered using 3M/AVI infusion pump
Trial: 1986897
Drug: Nitroprusside administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside administered using IVAC infusion pump
Trial: 1986897
Drug: Nitroprusside administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside administered using Kendall McGaw infusion pump
Trial: 6340183
Drug: Carprofen, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen, 300 mg/day
Trial: 6340183
Drug: Indomethacin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 75 mg/day
Trial: 27484710
Drug: Multipurpose solutions
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multipurpose solutions (MPS)
Trial: 25103686
Drug: e‐Exercise (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐Exercise (12-week intervention with maximum five face‐to‐face physical therapy contacts and a web‐based program)
Trial: 15014270
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (physical therapy)
Trial: 20008708
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (1 mg)
Trial: 16828501
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (4 mg)
Trial: 20008708
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (control group)
Trial: 15105032
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g beta‐hydroxy‐beta‐methylbutyrate, 5 g arginine, and 1.5 g lysine daily
Trial: 9876807
Drug: Intraperitoneal fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal fluconazole 200 mg
Trial: 7866603
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 20 mg twice daily
Trial: 7866603
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of captopril and ISDN
Trial: 2510288
Drug: indomethacin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin, 75 mg and 50 mg
Trial: 2510288
Drug: baseline, no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baseline, no treatment
Trial: 31381364
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - loading dose followed by continuous infusion for 48 hours
Trial: 26129900
Drug: Dalitong granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalitong granule (DG) 6 g 3 times daily
Trial: 26129900
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at points Zusanli (ST36), Zhongwan (CV12), Neiguan (PC6), Taichong (LR3), Gongsun (SP4) twice daily
Trial: 26129900
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of DG and EA
Trial: 26129900
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: 5 mg mosapride 3 times, 20 mg pantoprazole, and 25 mg amitriptyline twice daily
Trial: 22097156
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 mg/kg per day or 3 mg/kg per day)
Trial: 17895911
Drug: Flexible administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible administration of micronutrient Sprinkles over 4 months
Trial: 17895911
Drug: Flexible administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible administration of micronutrient Sprinkles over 3 months
Trial: 17895911
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of micronutrient Sprinkles over 2 months
Trial: 12975660
Drug: TAC (docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy (75/50/500 mg/m2 6x q3wk)
Trial: 12975660
Drug: FAC (5‐fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) chemotherapy (500/50/500 mg/m2 6x q3wk)
Trial: 11079643
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg daily for four weeks)
Trial: 8947886
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b (r-IFN-alpha 2b) at doses of 5, 2.5, or 1.25 million units (MU) daily for a minimum of 14 days prior to transplantation and continuing for 42 days post-transplantation.
Trial: 8947886
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b (r-IFN-alpha 2b) treatment.
Trial: 30488222
Drug: Three-drug control
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug control
Trial: 25279818
Drug: Noribogaine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noribogaine 60 mg
Trial: 27870477
Drug: Noribogaine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noribogaine 120 mg
Trial: 27870477
Drug: Noribogaine 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noribogaine 180 mg
Trial: 24993856
Drug: Dual-phase calcium
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste (TG+TP)
Trial: 12161765
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (Viagra) 25, 50 or 100 mg
Trial: 9883302
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray 0.03% (42 mcg per nostril) administered three times daily plus terfenadine 60 mg administered twice daily
Trial: 9883302
Drug: Vehicle nasal
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle nasal spray plus terfenadine 60 mg administered twice daily
Trial: 9883302
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray plus terfenadine
Trial: 9883302
Drug: Vehicle nasal
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle nasal spray plus terfenadine
Trial: 7543494
Drug: rhIGF‐I administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I administration
Trial: 2087049
Drug: RBA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBA with adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase, after‐mixing concentration 1:500,000)
Trial: 2087049
Drug: RBA without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RBA without adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase)
Trial: 650879
Drug: Ketamine 1
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1 mg/ml and Diazepam 0.1 mg/ml administered by intravenous drip at a rate of 0.1 ml/kg/min for the first 5 min and 0.017 ml/kg/min for the next 15 min.
Trial: 650879
Drug: Droperidol 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.125 mg/kg given intravenously before administration of ketamine-diazepam solution.
Trial: 31810829
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (mobile health-based program with weekly automated assessment and behavior change calls, structured email feedback to caregivers, and fax alerts to clinicians)